PL1655036T3 - Sposób leczenia chorób onkologicznych - Google Patents

Sposób leczenia chorób onkologicznych

Info

Publication number
PL1655036T3
PL1655036T3 PL04748955T PL04748955T PL1655036T3 PL 1655036 T3 PL1655036 T3 PL 1655036T3 PL 04748955 T PL04748955 T PL 04748955T PL 04748955 T PL04748955 T PL 04748955T PL 1655036 T3 PL1655036 T3 PL 1655036T3
Authority
PL
Poland
Prior art keywords
oncological diseases
treating oncological
treating
diseases
oncological
Prior art date
Application number
PL04748955T
Other languages
English (en)
Inventor
Dmitry Dmitrievich Genkin
Viktor Veniaminovich Tets
Georgy Viktorovich Tets
Original Assignee
Cls Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/RU2003/000304 external-priority patent/WO2005007187A1/ru
Application filed by Cls Therapeutics Ltd filed Critical Cls Therapeutics Ltd
Publication of PL1655036T3 publication Critical patent/PL1655036T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04748955T 2003-07-14 2004-07-01 Sposób leczenia chorób onkologicznych PL1655036T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/RU2003/000304 WO2005007187A1 (en) 2003-07-14 2003-07-14 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
RU2004108061/14A RU2269356C2 (ru) 2003-07-14 2004-03-12 Способ лечения онкологических заболеваний
EP04748955.4A EP1655036B1 (en) 2003-07-14 2004-07-01 Method for treating oncological diseases
PCT/RU2004/000261 WO2005004903A1 (en) 2003-07-14 2004-07-01 Method for treating oncological diseases

Publications (1)

Publication Number Publication Date
PL1655036T3 true PL1655036T3 (pl) 2014-02-28

Family

ID=34067504

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04748955T PL1655036T3 (pl) 2003-07-14 2004-07-01 Sposób leczenia chorób onkologicznych

Country Status (6)

Country Link
US (2) US7612032B2 (pl)
EP (1) EP1655036B1 (pl)
ES (1) ES2427091T3 (pl)
PL (1) PL1655036T3 (pl)
RU (1) RU2269356C2 (pl)
WO (1) WO2005004903A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
EP1666055A4 (en) * 2003-07-14 2010-02-10 Viktor Veniaminovich Tets METHOD OF TREATMENT OF ONCOLOGICAL, INFECTIOUS, AND SOMATIC DISEASES, METHODS OF MONITORING THE EFFICACY OF TREATMENT, AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
EP1880733A4 (en) * 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich Method for increasing longevity of a human being and animals
KR20090087095A (ko) * 2006-11-28 2009-08-14 드미트리 드미트리에비치 겐킨 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제
GB0713074D0 (en) 2007-07-05 2007-08-15 Univ London A method of hyperpolarising a magnetic resonance agent
WO2009134027A2 (en) * 2008-04-30 2009-11-05 Ajou University Industry-Academic Cooperation Foundation Anti-nucleic acid antibody inducing cell death of cancer cells and composition for preventing or treating cancers comprising the same
WO2012071420A1 (en) * 2010-11-23 2012-05-31 The Trustees Of Columbia University In The City Of New York Enzyme combinations to reduce brain tissue swelling
ES2744840T3 (es) 2011-04-01 2020-02-26 Univ Yale Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN
US9642822B2 (en) 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
US9603906B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Inhalable liquid formulations of DNase I
GB201208879D0 (en) * 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
WO2015134607A1 (en) 2014-03-04 2015-09-11 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with ras mutations
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
EP3240896A1 (en) 2015-01-04 2017-11-08 Protalix Ltd. Modified dnase and uses thereof
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
JP6761857B2 (ja) 2015-10-29 2020-09-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 抗癌療法の安全性および有効性を改善する方法
DE102016001407A1 (de) 2016-02-09 2017-08-24 Fresenius Medical Care Deutschland Gmbh Blutbehandlung mit Inaktivierung von freien Nukleinsäuren
US12486318B2 (en) 2016-06-15 2025-12-02 Yale University Anti-guanosine antibody as a molecular delivery vehicle
WO2017218825A1 (en) 2016-06-15 2017-12-21 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
US20190083636A1 (en) 2017-04-25 2019-03-21 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2018217351A1 (en) 2017-05-24 2018-11-29 Tets Viktor Veniaminovich Methods for treating and preventing diseases
ES3008982T3 (en) 2017-08-18 2025-03-25 Neutrolis Inc Engineered dnase enzymes and use in therapy
EP3685165B1 (en) 2017-09-18 2022-04-20 Santersus AG Method and device for purification of blood from circulating cell free dna
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US12535491B2 (en) 2018-04-30 2026-01-27 Viktor Veniaminovich Tets Vaccine comprising protein-targeted (PT) extracellular DNA isolated from bacterial matrix
WO2020006357A1 (en) 2018-06-29 2020-01-02 Tets Viktor Veniaminovich Methods for diagnosis and treatment of type 1 diabetes
WO2020010214A1 (en) 2018-07-03 2020-01-09 Tets Viktor Veniaminovich Method for assessing and inhibiting aging and means of determining biological age
EP3864147A4 (en) 2018-10-08 2022-07-06 Neutrolis, Inc. MANIPULATION OF DNASE ENZYMES FOR MANUFACTURE AND THERAPY
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US11352613B2 (en) 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
JP2023545740A (ja) 2020-10-07 2023-10-31 プロタリクス リミテッド 長期活性ＤＮａｓｅ
US20240327889A1 (en) * 2021-04-05 2024-10-03 Victor TETS Regulation of cells and organisms
JP2024519190A (ja) * 2021-05-21 2024-05-08 ゲンキン，ドミトリー，ドミトリエヴィチ 腫瘍微小環境の免疫調節
WO2023126672A1 (en) 2021-12-27 2023-07-06 Santersus Ag Method and device for removal of circulating cell free dna

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484589A (en) * 1992-04-20 1996-01-16 Rufeld, Inc. Anti-viral methods using RNAse and DNAse
NZ299257A (en) * 1992-06-08 2000-08-25 Genentech Inc Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
RU2099080C1 (ru) * 1994-02-11 1997-12-20 Дмитрий Иванович Финько Способ предотвращения развития рака
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
US6156504A (en) * 1996-03-15 2000-12-05 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays
WO2000003709A1 (en) * 1998-07-16 2000-01-27 Research Development Foundation Novel dna-cleaving antitumor agents
US6465177B1 (en) 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
AU4430701A (en) * 2000-04-03 2001-10-15 Antisoma Research Limited Compounds for targeting

Also Published As

Publication number Publication date
RU2269356C2 (ru) 2006-02-10
EP1655036A4 (en) 2009-06-17
US20080004561A1 (en) 2008-01-03
US7612032B2 (en) 2009-11-03
WO2005004903A1 (en) 2005-01-20
ES2427091T3 (es) 2013-10-28
EP1655036A1 (en) 2006-05-10
EP1655036B1 (en) 2013-07-17
RU2004108061A (ru) 2005-09-27
US20060233780A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
EP1655036A4 (en) METHOD OF TREATING ONCOLOGICAL DISEASES
ZA200508427B (en) Methods for treating interleuking-6 related diseases
IL164352A0 (en) Methods for treating tweak-related conditions
IL175818A0 (en) Method for treating adamts-5- associated disease
IL179139A0 (en) Method for treating multiple sclerosis
PT2564988T (pt) Métodos e aparelhos para operações de fabrico
GB0301972D0 (en) Method for identifying novel treatments
IL174849A0 (en) Method
EP1732394A4 (en) DEHYDRATION-GRIDING PROCESS
GB0422769D0 (en) Methods for treating deodorizer distillate
GB0315842D0 (en) Water-softening method
GB0301117D0 (en) Method
FI20030380L (fi) Menetelmä prosessin säätämiseksi
EP1809276A4 (en) PROCESSING PROCESS
EP1670416A4 (en) METHOD OF TREATING HYPERGLYCEMIA INDUCED BY IGF1R INHIBITORS
EP1701920A4 (en) METHOD FOR TREATING SUSTAINABLE SOLUTIONS
GB0307544D0 (en) Treatment method
FI20030381L (fi) Menetelmä prosessin säätämiseksi
GB0302691D0 (en) Treatment method
EP1681922A4 (en) ATHLETE'S FOOT TREATMENT METHOD
GB0312122D0 (en) Therapeutic method
GB0304215D0 (en) Method for treating waste
GB0316555D0 (en) Method
EP1612264A4 (en) ORGAN MOLDING
AU2003300471A8 (en) Methods for treating ocular diseases